Table 2 Proportion of patients with CACI.

From: An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study

 

Number of patients, n (%)

Overall*

At T2

At T3

Impairment in subjective test measures (FACT-Cog), N = 351

Overall cognition

117 (33.3)

70 (19.9)

93 (26.5)

Mental acuity

103 (29.3)

57 (16.2)

84 (23.9)

Concentration

98 (27.9)

57 (16.2)

76 (21.7)

Multitasking

98 (27.9)

59 (16.8)

78 (22.2)

Verbal fluency

74 (21.1)

42 (12.0)

59 (16.8)

Memory

73 (20.8)

41 (11.7)

56 (16.0)

Functional interference

68 (19.4)

33 (9.4)

52 (14.8)

Impairment in objective test measures (Headminder), N = 125

Learning and memory

21 (16.8)

12 (9.6)

16 (12.8)

Attention

20 (16.0)

14 (11.2)

9 (7.2)

Processing speed

13 (10.4)

7 (5.6)

7 (5.6)

Response speed

9 (7.2)

6 (4.8)

3 (2.4)

Impairment in objective test measures (CANTAB), N = 122

Processing speed

45 (36.9)

26 (21.3)

35 (28.7)

Attention

32 (26.2)

18 (14.8)

25 (20.5)

Response speed

37 (30.3)

21 (17.2)

23 (18.9)

Learning and memory

17 (13.9)

12 (9.8)

8 (6.6)

  1. *Impairment at either T2, T3 or both time points.